Treatment discontinuations due to adverse events occurred in 51 patients (14.7%) in the niraparib and abiraterone group, including one case of myelodysplastic syndrome (in a patient with a CHEK2 germline mutation), and in 36 patients (10.3%) in the abiraterone group (Extended Data Table 6). This evidence concerns the gene CHEK2 and myelodysplastic syndrome.